| Course | NU 636 Advanced Pharmacology |
|---|---|
| Unit | Unit 1 |
| Paper type | Drug class profile |
| Length | About 1,070 words, 6 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN Family Nurse Practitioner |
| Updated | October 2026 |
Free sample paper for NU 636 Unit 1
Drug Class Profile: Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation
Student Name
Department of Nursing, Herzing University
NU 636: Advanced Pharmacology
Instructor Name
January 21, 2026
Drug Class Profile: Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation
The Class and the Problem It Solves
Direct oral anticoagulants (DOACs) are oral drugs that inhibit a single clotting factor directly: dabigatran inhibits thrombin (factor IIa), while apixaban, rivaroxaban, and edoxaban inhibit factor Xa. In primary care they are most often prescribed to prevent stroke in nonvalvular atrial fibrillation, where stasis in the left atrial appendage allows thrombus to form and embolize. Before this class, warfarin was the standard oral option, and its narrow therapeutic range, food and drug interactions, and need for regular INR monitoring shaped every prescribing decision. This profile treats each property of the DOACs as a decision it creates for the prescriber.
Mechanism at the Target, and the Effects It Predicts
Factor Xa sits at the convergence of the intrinsic and extrinsic pathways and converts prothrombin to thrombin; thrombin then converts fibrinogen to fibrin and amplifies its own generation by activating factors V, VIII, and XI. Inhibiting factor Xa reduces the burst of thrombin generation; inhibiting thrombin directly blocks the final step. Both approaches reduce clot formation in the low-flow environment of the fibrillating atrium (Rosenthal & Burchum, 2021).
The intended effect and the principal adverse effect come from the same mechanism: reduced thrombin generation prevents pathological clots and also impairs hemostatic ones, so bleeding is the predictable harm. Because the drugs act on one factor rather than on several vitamin K-dependent factors as warfarin does, their effect is more predictable, but the bleeding risk remains. When apixaban was tested head to head against warfarin, the apixaban group had fewer strokes and embolic events and less major bleeding, including less intracranial hemorrhage (Granger et al., 2011). Dabigatran has a second, class-member-specific effect: its capsule contains tartaric acid to aid absorption, which accounts for the dyspepsia that is its most common reason for discontinuation.
Pharmacokinetics, Each With Its Consequence
Absorption and onset. All four agents reach peak effect within about one to four hours. Consequence: no bridging with a parenteral anticoagulant is needed when starting, unlike warfarin, and a missed dose leaves the patient unprotected within a day. Rivaroxaban at the 15 mg and 20 mg doses must be taken with the evening meal, because food substantially increases its absorption; a patient who takes it on an empty stomach receives a lower effective dose. Dabigatran capsules must not be opened, because the pellets alone produce much higher absorption and bleeding risk.
Half-life. Half-lives are roughly 12 hours for apixaban, 12 to 17 hours for dabigatran, 10 to 14 hours for edoxaban, and 5 to 9 hours for rivaroxaban in younger adults, longer in older adults (Steffel et al., 2021). Consequence: apixaban and dabigatran are dosed twice daily, and adherence to both doses matters because protection falls with each missed dose. The short duration also means the drugs can usually be held for one to three days before most procedures, depending on kidney function and bleeding risk, without bridging.
Elimination. This is the property that most separates class members. About 80% of dabigatran is cleared by the kidneys, roughly half of edoxaban, about a third of rivaroxaban as unchanged drug, and about 27% of apixaban (Steffel et al., 2021). Consequence: declining kidney function raises dabigatran levels more than any other member, which makes apixaban the member least affected by renal impairment and dabigatran the one to avoid when creatinine clearance is falling or unstable. Doses of each agent must be checked against creatinine clearance estimated with the Cockcroft-Gault formula, because that estimate, not eGFR, is what the dosing trials used.
Choosing Between Members
The properties above, not preference, decide selection. Apixaban suits older adults and those with reduced or fluctuating kidney function because of its lower renal clearance and favorable bleeding profile, at the cost of twice-daily dosing. Rivaroxaban and edoxaban suit patients for whom once-daily dosing is the best route to adherence, provided kidney function is adequate and, for rivaroxaban, that it can be taken with food. Dabigatran suits patients with good and stable kidney function, and it is the only member with a specific reversal agent, idarucizumab, that has been widely available for years; andexanet alfa reverses factor Xa inhibitors. Cost and coverage often decide between otherwise equivalent choices, and the prescriber should check the patient's plan before choosing rather than after.
Interactions by Pathway
All four agents are substrates of P-glycoprotein, and apixaban and rivaroxaban are also substantially metabolized by cytochrome P450 3A4. Strong inducers of both pathways, such as rifampin, carbamazepine, phenytoin, and St. John's wort, lower DOAC levels and should generally be avoided, because the patient loses stroke protection. Strong inhibitors of both pathways raise levels and bleeding risk. Pharmacodynamic interactions matter as much: aspirin, other antiplatelet agents, nonsteroidal anti-inflammatory drugs, and selective serotonin reuptake inhibitors add bleeding risk through separate mechanisms, and the reason for any combination should be reviewed at every visit (Steffel et al., 2021).
Monitoring With Intervals and Thresholds
Routine coagulation monitoring is not required, but the drugs are not monitoring free. Before starting: complete blood count, creatinine with calculated creatinine clearance, and liver function. During treatment: kidney function and blood count at least yearly, and more often when kidney function is reduced; a practical rule is to check kidney function every few months, with the interval in months roughly equal to creatinine clearance divided by 10 when clearance is below 60 mL/min (Steffel et al., 2021). Any drop in hemoglobin of 2 g/dL or more, or a fall in creatinine clearance below the threshold for the current dose, prompts a dose review. Each visit should also confirm adherence, bleeding events, and new interacting medications.
The Patient for Whom This Class Is the Wrong Answer
DOACs should not be used in patients with mechanical heart valves. In the trial of dabigatran in patients with mechanical valves, thromboembolic and bleeding events were both higher than with warfarin, and the trial was stopped early (Eikelboom et al., 2013). They are also not appropriate for moderate to severe mitral stenosis, for patients with antiphospholipid syndrome who test positive for all three antibodies, or for patients on unavoidable strong interacting drugs such as rifampin. For a patient with end-stage kidney disease, the evidence is limited, and the choice requires specialist input. In each case, warfarin remains the better-supported option, and the reasoning is the same: the population in which the class was tested did not include these patients, or included them and showed harm.
References
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., Harper, R., Khder, Y., Lobmeyer, M. T., Maas, H., Voigt, J.-U., Simoons, M. L., & Van de Werf, F. (2013). Dabigatran versus warfarin in patients with mechanical heart valves. New England Journal of Medicine, 369(13), 1206-1214. https://doi.org/10.1056/NEJMoa1300615
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., ... Wallentin, L. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981-992. https://doi.org/10.1056/NEJMoa1107039
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., Sinnaeve, P., Vanassche, T., Potpara, T., Camm, A. J., & Heidbuchel, H. (2021). 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace, 23(10), 1612-1676. https://doi.org/10.1093/europace/euab065
What the NU 636 Unit 1 instructions ask for
The Unit 1 prompt asks for a profile of one drug class, covering mechanism, pharmacokinetics, indications, adverse effects, interactions and monitoring at the depth a prescriber needs. Expect to explain how the mechanism predicts both the benefit and the main risks. Pharmacokinetic properties should be tied to what they mean in practice, for example dosing frequency or adjustment for kidney function. Many sections ask you to compare members of the class and explain how a prescriber would choose among them. Interactions should be grouped by mechanism, and monitoring should name tests and intervals, not just the words monitor closely. A contraindication or a patient group for whom the class is a poor choice is often required. Cite a pharmacology text plus guidelines and landmark trials in APA 7. The classroom sets length, commonly around four to six pages.
How this NU 636 Unit 1 example is built
The profile opens by naming the class, its members and the clinical problem: stroke from clots formed in a fibrillating atrium. The mechanism section explains why blocking factor Xa or thrombin reduces clot formation and why bleeding is the expected major adverse effect. Pharmacokinetics are written as property and consequence pairs, covering onset, half-life, renal clearance and food effects. Selection between members uses kidney function, age, dosing frequency and bleeding data from the major trials. Interactions are grouped by pathway, with P-glycoprotein and cytochrome P450 3A4 inducers and inhibitors named. Monitoring lists baseline blood count, creatinine clearance and liver tests, then repeat intervals that shorten as kidney function falls. The final section uses the mechanical valve trial to explain why this class should not replace warfarin in that group.
Reading the NU 636 Unit 1 rubric
In a Herzing rubric for a drug class profile, points usually go to mechanism of action, pharmacokinetics, clinical use, safety and monitoring, and scholarly writing. The mechanism criterion rewards an explanation that links the drug's target to its effects and adverse effects. Pharmacokinetic points depend on properties that are correct and translated into practice decisions. Clinical use is credited when the paper explains how to select within the class, using patient factors and trial data. Safety and monitoring often carry the most weight, because markers look for specific laboratory tests, intervals and thresholds along with interactions sorted by mechanism. Contraindications, such as the mechanical valve group here, are part of this criterion. Under writing, graders want APA style, recent sources and a layout a prescriber could use for quick reference.
NU 636 Unit 1 help before you submit
Profiles commonly lose points by reading like a drug card, listing facts without explaining what any of them means for prescribing. Students also describe one member of the class in detail and ignore how the others differ. Interactions are often listed as long tables of drug names with no pathway, which makes them hard to apply. Monitoring written as "monitor renal function periodically" usually earns partial credit at best. Another frequent gap is missing the patient for whom the class is inappropriate. Some papers rely on drug company websites or general reference sites instead of guidelines and trials. Dosing adjustments for kidney function should be stated accurately, since errors here are clinically serious. Finally, avoid copying package insert language; explain it in your own words with a citation.
Get a NU 636 Unit 1 example written to your instructions
Send the Unit 1 instructions and the rubric from your NU 636 classroom, plus the class you were assigned or intend to profile. We write a custom example against those criteria, with each property carried through to a dosing or monitoring consequence, and return it in 24 to 48 hours. The first custom sample is free.
More NU 636 papers and FNP samples
- NU 636 Unit 2: Prescribing rationale
- NU 636 Unit 3: Pharmacotherapy plan
- NU 636 Unit 4: Patient education handout
- NU 636 Unit 5: Drug therapy paper
- NU 636 Unit 6: Discussion post
- NU 636 Unit 7: Drug comparison paper
- NU 636 Unit 8: Comprehensive case study
- NU 627 Unit 1: Comprehensive geriatric assessment
- NU 631 Unit 1: Well-woman visit plan
- NU 632 Unit 1: Well-child visit with anticipatory guidance
- NU 610 Unit 1: Health history write-up
NU 636 Unit 1 questions, answered
How is a class profile different from a drug card?
A card stores facts for recall. A profile argues from those facts toward decisions, which is why the graduate version reads so differently. Every line that would sit in a card as data appears here with a consequence beside it, and the sections that carry the most credit, comparison inside the class and the exclusion criteria at the end, do not exist on a card at all.
How specific does the monitoring section have to be?
Specific enough that someone could follow it without asking a question. That means the parameter, the baseline before starting, the interval afterward, the threshold that triggers action and what the action is. An instruction to check potassium periodically is the version that loses marks, because periodically is not an interval and checking is not an action.
Which sources are acceptable in this course?
Current pharmacology references, peer-reviewed literature and recognized clinical guidance carry the load in most sections. Consumer medication pages and commercial summaries are the ones to keep out of load-bearing positions. Currency matters more here than in most graduate work, since dosing and safety guidance is revised, so check whether your instructions set a publication window before you build the reference list.
Where can I find a free NU 636 Unit 1 sample paper?
This page holds the full NU 636 Unit 1 anticoagulant class profile at no cost, with mechanism, kinetics, selection, interactions, monitoring and margin notes. If your instructor assigned another class, ask for a custom profile; it is free and typically ready inside 48 hours.
How is a drug class profile different from a drug card?
A drug card lists facts about one medicine. A class profile explains how the shared mechanism predicts effects and risks, how members differ, how to choose between them and what to monitor, so it reads as prescribing reasoning rather than a list.